Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01LCC
|
||||
| Former ID |
DND000006
|
||||
| Drug Name |
PF-4217903
|
||||
| Synonyms |
2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N; PF-04217903
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | ||
| Discovery agent [ICD-11: N.A.] | Investigative | [2] | |||
| Company |
Pfizer
|
||||
| Structure |
 |
Download2D MOL |
|||
| Formula |
C19H16N8O
|
||||
| Canonical SMILES |
C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=<br />C1
|
||||
| InChI |
1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
|
||||
| InChIKey |
PDMUGYOXRHVNMO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
29212271, 54248092, 99436977, 103905666, 124756993, 125011823, 125163798, 131480678, 134964423, 135653868, 135685260, 135685261, 135685280, 136340178, 136367293, 136920363, 137276005, 140816092, 143499148, 143499149, 152235007, 152237698, 152258340, 160647178, 162011939, 162037429, 162202551, 163312449, 163345958, 163907943, 164045116, 164764187, 170484567, 172113563, 177748688, 186022475, 198969694, 223402404, 223617434, 223705036, 224378934, 226471317, 247681667, 251963200, 252216038, 252216039, 252451594, 252543331
|
||||
| Target and Pathway | |||||
| Target(s) | Proto-oncogene c-Met (MET) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Axon guidance | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Bacterial invasion of epithelial cells | |||||
| Epithelial cell signaling in Helicobacter pylori infection | |||||
| Malaria | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Renal cell carcinoma | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | ||||
| Arf6 signaling events | |||||
| Signaling events mediated by TCPTP | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Direct p53 effectors | |||||
| Syndecan-1-mediated signaling events | |||||
| Stabilization and expansion of the E-cadherin adherens junction | |||||
| a6b1 and a6b4 Integrin signaling | |||||
| FGF signaling pathway | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | Sema4D mediated inhibition of cell attachment and migration | ||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Signaling of Hepatocyte Growth Factor Receptor | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Signaling Pathways in Glioblastoma | |||||
| miR-targeted genes in squamous cell - TarBase | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00706355) A Study of PF-04217903 in Patients With Advanced Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | ||||
| REF 3 | Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.